Moreover, EGFR‐mutant NSCLC patients with concurrent RB1 and TP53 alterations have an increased risk of NE transdifferentiation, with 25% presenting with de novo SCLC or eventual small‐cell transformation [65]. The gene discussed is EGFR; the disease is small cell lung carcinoma.